14 results about "Hypercalcinemia" patented technology

The invention discloses a cinacalcet-containing transdermal patch as well as a preparation method and application thereof. The transdermal patch comprises a high-molecular matrix layer, wherein the high-molecular matrix layer comprises cinacalcet, a silicone pressure-sensitive adhesive and one or more high-molecular polymers selected from a water-insoluble cellulose derivative, polyvinylpyrrolidone and a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. The transdermal patch disclosed by the invention is good in drug permeability and colloid application performance, high in safety, free of skin irritation, high in stability and good in uniformity, and can meet the requirements of clinically treating hyperparathyroidism or hypercalcemia.

This disclosure relates to antibodies that specifically bind to parathyroid hormone-related protein (PTHrP). Immunoconjugates, nucleic acids, vectors, cells, and compositions comprising said antibodies are also provided. The antibodies, immunoconjugates, nucleic acids, vectors, cells, and compositions can be used for the diagnosis and treatment of diseases, particularly cancer and / or hypercalcemia.

The application provides application of a PLK1 inhibitor in preparation of a drug for treating ovarian hypercalcemia type small cell carcinoma. The drug containing the PLK1 inhibitor can effectively treat the ovarian hypercalcemia type small cell carcinoma, inhibit growth of a lesion of the ovarian hypercalcemia type small cell carcinoma, has a quick effect, and can produce obvious therapeutic effect 20 days after administration.

The aqueous pharmaceutical formulation with improved stability comprises denosumab and a poloxamer, and preferably a histidine buffer and / or a sugar or sugar alcohol. The formulation is for use in the treatment or prevention of skeletal-related events associated with osteoporosis, reduced bone mass, multiple myeloma, solid tumor bone metastasis, giant cell tumor of bone, or hypercalcemia.

Pharmaceutical compositions of polymeric micelle cinacalcet suitable for intravenous or intraperitoneal administration, and methods of making and use thereof in the treatment of various diseases and disorders, such as hyperparathyroidism and hypercalcemia, are provided.

The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

The present disclosure relates to an animal food composition including from about 0.3 g / Mcal to about 0.8 g / Mcal of magnesium or a salt thereof, for use in a method for treating and / or preventing a mineral bone disorder, especially mineral bone disorder associated with hypercalcemia, in a companion animal that is affected by, or at risk to be affected by, a kidney dysfunction.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

Abstract The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%. This data, for application number 2023202402, is current as of 2024-12-02 22:50 AEDT Abstract The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%. This data, for application number 2023202402, is current as of 2024-12-02 22:50 AEDT 20 24 27 06 32 03 D ec 2 02 4 0 3 D e c 2 0 2 4 2 0 2 4 2 7 0 6 3 2

The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%.

This invention provides a composition comprising an LSD1 inhibitor and 1,25(OH)2D3 and its application in the treatment of acute monocytic leukemia. The composition provided by this invention can induce AML-M5 cell differentiation, achieving the therapeutic effect on acute monocytic leukemia while avoiding the side effect of hypercalcemia caused by high doses of 1,25(OH)2D3.

The invention relates to a steroidal VDR regulator as well as a preparation method and application thereof, and relates to a compound as shown in a general formula I or a stereoisomer, a solvate, a hydrate, a prodrug, a stable isotope derivative and a pharmaceutically acceptable salt thereof. The compound as the VDR regulator has a very high inhibition effect on a TGF-beta / SMAD3 signal channel; the traditional Chinese medicine composition has the effect of effectively resisting hepatic fibrosis, and meanwhile, the side effects such as hypercalcemia are reduced to the greatest extent; and the compound has excellent selectivity, excellent drug effect, solubility, in-vitro / in-vivo pharmacokinetic property and safety, and has a good clinical application prospect.

The present invention relates compositions, methods and kits for characterizing the type of and screening for the existence or predisposition for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The invention also relates to a method of treating a mammalian subject having SCCOHT or a predisposition for SCCOHT.